The Trump administration says it will release $600 million in long-delayed funding to Gavi after the global vaccine alliance agreed to work toward replacing several thimerosal-containing shots with newer alternatives. The announcement is a major funding reversal—but the switch is a multi-step promise, not an overnight global vaccine makeover.
As first reported by Fox San Antonio, the administration said Wednesday that the money covers fiscal years 2025 and 2026. A joint statement from HHS said the United States also expects to resume its seat on Gavi's board, while Reuters reported that Health Secretary Robert F. Kennedy Jr. had made the thimerosal phase-out a condition of renewed support.
What Gavi Agreed To Change
Gavi has already been moving countries toward newer combination vaccines. Its own program guidance says eligible countries can switch from pentavalent vaccine plus separate polio shots to a hexavalent formulation that protects against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and polio, while reducing the number of injections.
Under the new commitments, Gavi will make every effort to shift from mercury-containing meningococcal A, pneumococcal, hepatitis B and pentavalent DTP-Hib-HepB vaccines to alternatives that are mercury-free or provide broader protection. The HHS statement acknowledges that manufacturers must expand production, countries must adopt the newer products and Gavi's board must approve the changes.
The Science Behind The Mercury Debate
The preservative at issue is thimerosal, also called thiomersal, an ethylmercury compound used in some multidose vaccine vials to prevent contamination. The World Health Organization says ethylmercury is processed and eliminated more quickly than methylmercury, the form associated with accumulation in some fish, and that extensive research has found no evidence that the small amount used in vaccines causes harm or autism.
The Food and Drug Administration says all routinely recommended vaccines for children age 6 and younger are available in formulations without thimerosal, while also noting that preservatives help keep multidose vials from developing dangerous microbial contamination. In practical terms, the agreement is a procurement and manufacturing shift—not an announcement of a recall or a newly discovered vaccine safety emergency.
Why The Funding Matters
Gavi reported that its programs reached more than 72 million children with routine vaccines in 2024, but its latest funding update warned that the 2026–2030 period is not fully financed. The alliance said funding pressure could limit malaria vaccine expansion, switches to newer products and the replenishment of global vaccine stockpiles.
The next test will be execution: enough mercury-free doses must be produced, participating countries must accept the replacements and Gavi's governing board must sign off. Until that happens, the administration's announcement represents a conditional financial reset and a political victory for Kennedy, while the global vaccination system still has to do the unglamorous work of manufacturing and delivering the shots.
.jpg){kind=link}